TABLE 5.

Effect of delay in initiation of T-705 treatment on an influenza A (H5N1) virus infection in mice

Expt no. and treatmentaTime of start of therapy (h)Infected, treated mice
No. of survivors/total no. testedMDDb ± SDcMean day 11 SaO2 (%) ± SDc
Expt 1
    T-705, 300 mg/kg/day2410/10***>21.0***85.3 ± 5.7***
    T-705, 300 mg/kg/day369/9***>21.0***84.6 ± 5.9***
    T-705, 300 mg/kg/day489/10***4.0 ± 0.087.1 ± 6.2***
    T-705, 300 mg/kg/day6010/10***>21.0***84.6 ± 6.6***
    0.4% CMC240/207.0 ± 0.575.0 ± 0.0
    Healthy controls92.6 ± 3.5
Expt 2
    T-705, 300 mg/kg/day729/10***7.0 ± 0.084.1 ± 5.5***
    T-705, 300 mg/kg/day8410/10***>21.0***81.7 ± 3.6**
    T-705, 300 mg/kg/day968/9***7.0 ± 0.081.2 ± 3.4**
    T-705, 300 mg/kg/day1203/10*7.9 ± 2.676.0 ± 1.3
    0.4% CMC720/207.9 ± 2.775.1 ± 0.5
    Healthy controls86.4 ± 3.4
  • a Every 6 h for 5 days.

  • b MDD, mean day to death of mice dying prior to day 21.

  • c *, P < 0.05 compared to the results for the CMC-treated controls; **, P < 0.01 compared to the results for the CMC-treated controls; ***, P < 0.001 compared to the results for the CMC-treated controls.